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U-TUBEINHIGHBILEDUCTOBSTRUCTION
Millikan, K. W., Gleason, T. G., Deziel, D.J. andDoolas, A. (1993) The current role ofU tubes
for benign andmalignant biliary obstruction. Annals ofSurgery; 218, 621-629.
Objective. The recent experience with U tubes at Rush-Presbyterian-St. Lukes Medical
Center was reviewed in order to assess their current role in hepatobiliary surgery.
Summary BackgroundData. Transhepatic intubation by a variety ofmethods has been used
routinely for biliary decompression and inhibition ofanastomotic stricture since the 1960s.U
tubes were popularized in the early 1970s. However, little has been written about their use and
efficacy in recent years. Because of the apparent benefits associated with the use ofU tubes
versus other stenting techniques, the authors performed this study.
Methods. The hospital and office charts ofaH patientswhohadU tubes placed between 1980 and
1992 were reviewed retrospectively. Between 1980 and 1992,U tubes were placed intraopera-
tively in 54 patients for biliary decompression and/or stenting. Twelve patients were operated on
for benign causes ofobstruction. Forty-two patients with malignant tumors underwent surgery
forU tube placement in conjunction with or without tumor resection and anastomotic bypass.
Results. There was a0% operative mortality rate in the benign group. In six patients, theU tube
played a major role in the long-term management of their disease processes. None of these
patients has had restricture since removal of the tube. In the malignant group, the 30-day
operative mortality rate was 12%. After 3 months, marked clinical improvement and complete
biliary decompression were achieved, with mean bilirubin levels dropping from 14.0 mg/dL to
1.3 mgldL. No patients in the malignant group required reoperation for recurrent biliary
obstruction after u tube placement.
Conclusions. The use ofU tubes is advocated for biliary decompression and/or anastomotic
stenting in patients with benign stricture or resectable malignancy and in patients with
nonresectable, malignant biliary obstruction for adequate palliation ofintractable jaundice.
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PAPERDISCUSSION
The paper by Millikan et al. is a retrospective review of
the use of U tubes for biliary decompression from the
Rush-Presbyterian-St. Lukes Medical Center, spanning
the years 1980 to 1992. The authors provide detailed data
on the use ofU tubes in 54 patients, with 12 patients having
benign strictures and 42 patients having malignant
obstruction. The report collects together patients treated
with stricture resection, as well as those treated by
palliative bypass (with or without biliary-enteric
anastomosis). The authors conclude that the U tube is
effective for the treatment ofbiliary strictures, and that it
has advantages over the other types ofbiliary stents.
The controversy over the best type of operatively-
placed transhepatic stent remains unsettled by this
report ,2. Supporters ofU tubes (which exit the skin at two
sites) favor their use because of the stated ease of
exchange and high levels of patient acceptance with the
cleaning procedure. Supporters of straight transhepatic
tubes (which exit the skin at only one site, with the internal
aspect ofthe stent typically residing in a Roux-en-Y loop
ofbowel used for biliary-enteric anastomosis) favor their
use because the number ofexit sites per patient is reduced
and the tube exchange process has become a simple
outpatient procedure. Prospective data comparing U
tubes and straight tubes are lacking, and thus the
resolution ofthis controversy remains largely emotional
and based upon the surgeon’s preference. We favor
straight transhepatic tubes, which are often inserted using
pre-existing percutaneously-placed transhepatic "Ring"
catheters, or can be inserted transhepatically at the time of
laparotomy3. Several issues addressed by the article of
Millikan et al. deserve further mention: the challenging
pattern of iatrogenic bile duct injuries, the emergence of
non-surgical options for bile duct obstruction, and the
need for a multidisciplinary approach to many patients
with obstructivejaundice.
First, in their group of 12 patients with benign bile duct
strictures only one stricture involved thecommon hepatic
duct and only one stricture was above the hepatic duct
bifurcation. The recent introduction, popularization and
widespread use oflaparoscopic cholecystectomy has been
associated with an increased incidence of bile duct
injuries, many ofwhich involve thecommon hepatic duct
or its bifurcation4-6. Repair of such bile duct injuries has
been reported both early and late after their occurrence,
and not uncommonly has required bilateral hepaticojeju-
nostomy, with transhepatic stents used to traverse both
the right and left lobes ofthe liver.
Second, Millikan et al. treated 42 patients with malig-
nant biliary obstruction with U tube stenting, with 18
patients undergoing tumor resection (9 "curative", 9
palliative) and 24 patients undergoingU tube placement
for palliation, without tumor resection. In this entire group
ofpatients the 30 day postoperative mortality ratewas 12%
and in-hospital mortality rate was 26%, rates that are
similar to some series78 but not much higher than other
reported concurrent series8,9. One explanation for this
high in-hospital mortality rate may involve the choice of
surgicalU tube palliation over other nonoperative options
such as percutaneous or endoscopic palliation. A
nonoperative approach to palliation may be undertaken
because the tumor is considered unresectable by
preoperative staging studies or because the latient is
considered unfit for surgery. Patients unfit for surgery
include those with poor performance status, distant
metastases, extensive tumor extension into both the right
and left lobes ofthe liver, and portal vein or main hepatic
artery occlusion.
Percutaneous transhepatic palliation usually involves
the ultimate placement of 12 to 16 French soft silastic
transhepatic catheters through the tumor and into the
duodenum. In most cases these percutaneous stents are
exchanged over guidewires as an outpatient procedure
every three to four months, to avoid the complications of
side hole occlusion, biliary obstruction, and cholangitis. A
further percutaneous palliative option is the transhepatic
placement of a biliary endoprosthesis. New metallic
devices the Wallstent, Gianturco Z-stent, and Palmaz
stent. Should the endoscopic route be chosen, plastic
biliary endoprostheses varying in diameter from 7 to 11.5
French can be successfully inserted into the obstructed
biliary tree. Plastic endoprostheses appear to have a
higher occlusion rate than metal endoprostheses, as
several randomized controlled studies have now shown
that self-expanding metals stents (Wallstent) are superior
to 10 French plastic stents for palliation ofjaundice in
malignant bile duct obstruction. For example, a recent
study from Amsterdam randomized 105 patients with
distal strictures to metal versus plastic stents. The suc-
cess ofthe initial drainage was 95% with both treatments,
but the median patency was significantly longer for the
metal stent (273 days) as compared to the plastic stent (126
days), with fewer endoscopic reinterventions needed for
the metal stent.
The choice ofnonoperative versus operative palliation
in patients with malignant biliary obstruction remains
difficult. Several randomized, controlled studies have
compared these different modes of palliation. Bornman
et al. compared percutaneous stenting with surgery in 50
patients with distal bile duct obstruction. Technical
success was achieved in 84% ofthe patients in the percuta-
neously stented group, and in 76% of the patients in theHPB INTERNATIONAL 203
surgery group. The procedure-related complications (28%
and 32%, respectively) and 30 day mortality (8% and 20%)
were similar. Although the initial hospital stay was
significantly shorter in the stented group (18 vs 24 days),
this difference was not maintained when readmissions for
obstructed endoprostheses and duodenal obstruction
were also considered. Another study by Dowsett et al.
included 127 patients with unresectable malignancy
obstructing the distalbile duct2. Sixty-five patients were
treated via endoscopic stenting and 62 had surgical
palliation. Successful biliary drainagewas achieved in 94%
of patients, with the 30 day mortality being 6% after
endoscopy and 15% after surgery. However, recurrent
jaundice (17% vs 3%) and late duodenal obstruction (14%
vs 3%) were seen more commonly in the endoprosthesis
group. Unfortunately, no prospective randomized studies
have compared surgical to nonsurgical palliation ofhilar
cholanginocarcinoma or more proximal biliary obstruc-
tion, and therefore data applicable to this situation are
lacking.
In conclusion, the management of patients with obs-
tructive jaundice from either benign or malignant
processes no longer resides solely within the hands of
surgeons. A multidisciplinary approach to such a prob-
lems is currently indicated, with some patients being
best treated by endoscopic or percutaneous techniques,
others by surgical techniques, and still others using
a multidisciplinary approach. Operatively placed
transhepatic stents continue to play an important role in
the management of these patients. So do the procedures
performed by our talented endoscopists and interven-
tional radiologists.
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